(Q37981576)

26 August 2017

title

Antibodies in the treatment of aplastic anemia (English)

1 reference

26 August 2017

David Gómez-Almaguer

1

1 reference

26 August 2017

Jose Carlos Jaime-Pérez

series ordinal

2

1 reference

26 August 2017

Guillermo J Ruiz-Arguelles

series ordinal

3

1 reference

26 August 2017

language of work or name

1 reference

4 February 2012

1 reference

Archivum Immunologiae et Therapiae Experimentalis

26 August 2017

published in

1 reference

26 August 2017

volume

60

1 reference

26 August 2017

issue

2

1 reference

26 August 2017

page(s)

99-106

1 reference

Changes in cytokine profile pre- and post-immunosuppression in acquired aplastic anemia.

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Hairy cell leukemia responsive to anti-thymocyte globulin used as immunosuppressive therapy for aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: the Mexican experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Marrow transplants from matched unrelated donors for aplastic anaemia using alemtuzumab, fludarabine and cyclophosphamide based conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Aplastic anemia successfully treated with rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Danazol as first-line therapy for aplastic anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Haematopoietic stem cell transplantation to treat aplastic anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Relapse of aplastic anemia in children after immunosuppressive therapy: a report from the Japan Childhood Aplastic Anemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

A pilot dose-escalating study of alemtuzumab plus cyclosporine for patients with bone marrow failure syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

The Third Consensus Conference on the treatment of aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

A critical role for B cells in the development of memory CD4 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Seeing the good and bad in aplastic anemia: is autoimmunity in AA dysregulated or antineoplastic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Immunosuppressive treatment for aplastic anemia: are we hitting the ceiling?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Autoantibodies specific to hnRNP K: a new diagnostic marker for immune pathophysiology in aplastic anemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Immunosuppressive therapies in the management of immune-mediated marrow failures in adults: where we stand and where we are going

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Antithymocyte globulin and cyclosporine for severe aplastic anemia: association between hematologic response and long-term outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Long-term results of the immunosuppressive treatment of patients with severe acquired aplastic anemia: a single institution study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Cyclosporin A response and dependence in children with acquired aplastic anaemia: a multicentre retrospective study with long-term observation follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus: a prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Predicting response to immunosuppressive therapy and survival in severe aplastic anaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Costs and consequences of immunosuppressive therapy in children with aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

From T to B and back again: positive feedback in systemic autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Treatment of aplastic anaemia by antilymphocyte globulin with and without allogeneic bone-marrow infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Rituximab in autoimmune hematologic diseases: not just a matter of B cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

Persistent remission after immunosuppressive therapy of hairy cell leukemia mimicking aplastic anemia: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

The effect of treatment with Campath-1H in patients with autoimmune cytopenias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

The pathophysiology of acquired aplastic anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0164-3

10.1007/S00005-012-0164-3

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference